Table: q1_q4_2021_prescription_drug_wac_increases , manufacturer_name like H*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000144 Helsinn Therapeutics, Inc 09/30/2021 69639010501 AKYNZEO Intravenous Solution 235-0.25 MG/20ML 07/01/2021 13.41 683.19 06/02/2037 Single Source Drug 25000 None The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications. None n/a None None None None None None None None None None None None
Rx0000144 Helsinn Therapeutics, Inc 09/30/2021 69639010201 AKYNZEO Intravenous Solution Reconstituted 235MG/0.25MG PER VIAL 07/01/2021 13.41 683.19 06/02/2037 Single Source Drug 400 None The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications. None n/a None None None None None None None None None None None None
Rx0000144 Helsinn Therapeutics, Inc 09/30/2021 69639012001 VALCHLOR 0.016% Gel 60gm tube 07/01/2021 318.91 4874.69 07/08/2029 Single Source Drug 620 None The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications. None n/a None None None None None None None None None None None None
Rx0000119 Heron Therapeutics, Inc. 03/31/2021 47426020101 CINVANTI; 130 mg; single-dose vial 01/01/2021 8.65 392.84 None Single Source Drug 575739 None Increase due to market factors None There were no changes to the drug None None None None None None None None None None None None
Rx0000119 Heron Therapeutics, Inc. 06/30/2021 47426020101 CINVANTI; 130 mg; single-dose vial 04/01/2021 8.84 401.68 None Single Source Drug 575739 None Increase due to market factors None There were no changes to the drug None None None None None None None None None None None None
Rx0000119 Heron Therapeutics, Inc. 09/30/2021 47426020101 CINVANTI; 130 mg; single-dose vial; injectable emulsion 07/01/2021 9.04 410.72 None Single Source Drug 575739 None Increase due to market factors None There were no changes to the drug None None None None None None None None None None None None
Rx0000119 Heron Therapeutics, Inc. 12/31/2021 47426020101 CINVANTI; 130 mg; single-dose vial; injectable emulsion 10/01/2021 9.24 419.96 None Single Source Drug 575739 None Increase due to market factors None There were no changes to the drug None None None None None None None None None None None None
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2021 00143993125 Cefotaxime Sodium Injection Solution Reconstituted 1gm 02/15/2021 10.45 65.45 None Non-innovator Multiple Source Drug None 1 This product was previously removed from the market due to a discontinuation of the raw material we use from our supplier. Hikma had to reinvest in the product to find a new API supplier and R&D work to qualify and reintroduce the product. None None 1 None None None None None None None None None None Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2021 00143993325 Cefotaxime Sodium Injection Solution Reconstituted 2gm 02/15/2021 23.75 148.75 None Non-innovator Multiple Source Drug None 1 This product was previously removed from the market due to a discontinuation of the raw material we use from our supplier. Hikma had to reinvest in the product to find a new API supplier and R&D work to qualify and reintroduce the product. None None 1 None None None None None None None None None None Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2021 00143978710 Enalaprilat Intravenous Injection 1.25mg/mL, 1mL 02/15/2021 4.35 48.31 None Non-innovator Multiple Source Drug None 1 Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. None None 1 None None None None None None None None None None Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2021 00143978610 Enalaprilat Intravenous Injection 1.25mg/mL, 2mL 02/15/2021 7.77 86.28 None Non-innovator Multiple Source Drug None 1 Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. None None 1 None None None None None None None None None None Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2021 00641602110 Famotidine Intravenous Solution 200mg/20mL 02/15/2021 7.92 87.88 None Non-innovator Multiple Source Drug None 1 Increase in cost of refrigeration and cold chain supply. None None 1 None None None None None None None None None None Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2021 00641602325 Famotidine Intravenous Solution 40mg/4mL 02/15/2021 5.58 61.90 None Non-innovator Multiple Source Drug None 1 Increase in cost of refrigeration and cold chain supply. None None 1 None None None None None None None None None None Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2021 00641604610 Lorazepam Injection Solution 2mg/mL 02/15/2021 9.59 106.46 None Innovator Multiple Source Drug None 1 Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. Increase in cost of refrigeration and cold chain supply. None None 1 None None None None None None None None None None Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2021 00641604710 Lorazepam Injection Solution 4mg/mL, 10mL 02/15/2021 13.04 144.77 None Innovator Multiple Source Drug None 1 Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. Increase in cost of refrigeration and cold chain supply. None None 1 None None None None None None None None None None Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2021 00641604525 Lorazepam Injection Solution 4mg/mL, 1mL 02/15/2021 6.36 70.65 None Innovator Multiple Source Drug None 1 Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. Increase in cost of refrigeration and cold chain supply. None None 1 None None None None None None None None None None Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 12/31/2021 00641094835 Promethazine HCl Injection Solution 25 MG/ML, Qty 25 10/01/2021 22.64 43.64 None Non-innovator Multiple Source Drug None 1 None 1 Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. None None None None None None None None None None None Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 12/31/2021 00641094935 Promethazine HCl Injection Solution 50mg/mL, 1mL, Qty 25 10/01/2021 16.64 62.89 None Non-innovator Multiple Source Drug None 1 None 1 Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. None None None None None None None None None None None Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 12/31/2021 00641095525 Promethazine Hydrochloride Solution Injection Solution 25 MG/ML, Qty 25 10/01/2021 22.14 43.64 None Non-innovator Multiple Source Drug None 1 None 1 Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. None None None None None None None None None None None Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 12/31/2021 00641095625 Promethazine Hydrochloride Solution Injection Solution 50mg/mL, 1mL, Qty 25 10/01/2021 44.89 91.14 None Non-innovator Multiple Source Drug None 1 None 1 Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. None None None None None None None None None None None Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000145 Horizon Therapeutics USA, Inc. 03/31/2021 75987008010 Product Name: KRYSTEXXA; Drug product strength: 1 mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts. Drug product dosage form: vial. Drug product package size: 8 MG/ML single use vial 02/01/2021 1138.06 24847.56 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Columns left blank contain non-public information. Acquisition columns left blank because this product was not acquired within the last five years.